What is the impact of education on Huntington's disease?

Movement Disorders

Volumn 26, Issue 8, 2011, Pages 1489-1495

  López Sendón, Jose Luis ^a,b   Royuela, Ana ^a,c   Trigo, Patricia ^a,b   Orth, Michael ^d   Lange, Herwig ^e   Reilmann, Ralf ^f   Keylock, Jennifer ^g   Rickards, Hugh ^g   Piacentini, Silvia ^h   Squitieri, Ferdinando ⁱ   Landwehrmeyer, Bernhard ^d   Witjes Ane, Marie Noelle ^j   Jurgens, Caroline K ^j   Roos, Raymund A C ^j   Abraira, Victor ^a,c   de Yébenes, Justo G ^a,b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^d UNIVERSITY OF ULM   (Germany)

^e Reha Zentrum Dinslaken   (Germany)

^f UNIVERSITY OF MÜNSTER   (Germany)

^g UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^h UNIVERSITY OF FLORENCE   (Italy)

ⁱ IRCCS NEUROMED   (Italy)

^j LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Age at onset; Education; Huntington's disease; Neuroprotection; UHDRS scores

Indexed keywords

ADENOSINE; CYTOSINE; GUANINE;

ADULT; ARTICLE; BEHAVIOR; CLINICAL FEATURE; COGNITION; DISEASE SEVERITY; EDUCATIONAL STATUS; FEMALE; HUMAN; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; NEUROLOGIC EXAMINATION; OBSERVATIONAL STUDY; PHENOTYPE; PRIORITY JOURNAL; TANDEM REPEAT; UNIFIED HUNTINGTON DISEASE RATING SCALE;

ADULT; AGE OF ONSET; COGNITION DISORDERS; EDUCATIONAL STATUS; FAMILY HEALTH; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MENTAL DISORDERS; MIDDLE AGED; PHENOTYPE; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 79960589401     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23385     Document Type: Article

References (40)

1. Shoulson I. Huntington's disease. A decade of progress. Neurol Clin 1984; 2: 515-526.
2. Purdon SE, Mohr E, Ilivitsky V, et al. Huntington's disease: pathogenesis, diagnosis and treatment. J Psychiatry Neurosci 1994; 19: 359-367.
3. Haddad MS, Cummings JL. Huntington's disease. Psychiatr Clin North Am 1997; 20: 791-807.
4. Nance MA. Huntington disease: clinical, genetic, and social aspects. J Geriatr Psychiatry Neurol 1998; 11: 61-70.
5. Sánchez-Pernaute R, Künig G, del Barrio Alba A, et al. Bradykinesia in early Huntington's disease. Neurology 2000; 54: 119-125.
6. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and instable on Huntington's disease chromosomes. Cell 1993; 72: 971-983.
7. Gusella JF, Altherr MR, McClatchey AI, et al. Sequence-tagged sites (STSs) spanning 4p16.3 and the Huntington disease candidate region. Genomics 1992; 13: 75-80.
8. Gusella JF, MacDonald ME. Hunting for Huntington's disease. Mol Genet Med 1993; 3: 139-158.
9. Gusella JF, MacDonald ME, Ambrose CM, et al. Molecular genetics of Huntington's disease. Arch Neurol 1993; 50: 1157-1163.
10. Goldberg YP, Telenius H, Hayden MR. The molecular genetics of Huntington's disease. Curr Opin Neurol 1994; 7: 325-332.
11. Langbehn DR, Hayden MR, Paulsen JS. CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet Part B: Neuropsychiatr Genet 2010; 153: 397-408.
12. Djoussé L, Knowlton B, Hayden M, et al. Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease. Am J Med Genet 2003; 119: 279-282.
13. Rosenblatt A, Liang KY, Zhou H, et al. The association of CAG repeat length with clinical progression in Huntington disease. Neurology 2006; 66: 1016-1020.
14. Ravina B, Romer M, Constantinescu R, et al. The relationship between CAG repeat length and clinical progression in Huntington's disease. Mov Disord 2008; 23: 1223-1227.
15. Wexler NS, Lorimer J, Porter J, et al. U.S.-Venezuela Collaborative Research Project. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci USA 2004; 101: 3498-3503.
16. Aziz NA, Jurgens CK, Landwehrmeyer GB, et al. Normal and mutant HTT interact to affect clinical severity and progression in Huntington disease. Neurology 2009; 73: 1280-1285.
17. Paradisi I, Hernández A, Arias S. Huntington disease mutation in Venezuela: age of onset, haplotype analyses and geographic aggregation. J Hum Genet 2008; 53: 127-135.
18. Warby SC, Montpetit A, Hayden AR, et al. CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. Am J Hum Genet 2009; 84: 351-366.
19. Li JL, Hayden MR, Warby SC, et al. Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23-24: the HD MAPS study. BMC Med Genet 2006; 17: 7-71.
20. Van Dellen A, Blakemore C, Deacon R, et al. Delaying the onset of Huntington's disease in mice. Nature 2000; 404: 721-722.
21. Schilling G, Savonenko AV, Coonfield ML, et al. Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice. Exp Neurol 200; 187: 137-149.
22. Lazic SE, Grote HE, Blakemore C, et al. Neurogenesis in the R6/1 transgenic mouse model of Huntington's disease: effects of environmental enrichment. Eur J Neurosci 2006; 23: 1829-1838.
23. Spires TL, Grote HE, Varshney NK, et al. Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism. J Neurosci 2004; 24: 2270-2276.
24. Koepsell TD, Kurland BF, Harel O, et al. Education, cognitive function and severity of neuropathology in Alzheimer's disease. Neurology 2008; 70: 1732-1739.
25. Mortimer JA, Snowdon DA, Markesbery WR. Head circumference, education and risk of dementia: findings from the Nun Study. J Clin Exp Neuropsychol 2003; 25: 671-679.
26. Riley KP, Snowdon DA, Desrosiers MF, et al. Early life linguistic ability, late life cognitive function, and neuropathology: findings from the Nun Study. Neurobiol Aging 2005; 26: 341-347.
27. Ampuero I, Ros R, Royuela A, et al. Risk factors for dementia of Alzheimer type and aging-associated cognitive decline in a Spanish population based sample, and in brains with pathology confirmed Alzheimer's disease. J Alzheimer Dis 2008; 14: 179-191.
28. Jorm AF. Alzheimer's disease: risk and protection. Med J Aust 1997; 167: 443-446.
29. Jankowsky JL, Melnikova T, Fadale DJ, et al. Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer's disease. J Neurosci 2005; 25: 5217-5124.
30. Zhang MY, Katzman R, Salmon D, et al. The prevalence of dementia and Alzheimer's disease in Shanghai, China: impact of age, gender, and education. Ann Neurol 1990; 27: 428-437.
31. Hockly E, Cordery PM, Woodman B, et al. Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Ann Neurol 2002; 5: 235-242.
32. van Dellen A, Hannan AJ. Genetic and environmental factors in the pathogenesis of Huntington's disease. Neurogenetics 2004; 5: 9-17.
33. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996; 11: 136-142.
34. Siesling S, van Vugt JP, Zwinderman KA, et al. Unified Huntington's disease rating scale: a follow up. Mov Disord 1998; 13: 915-919.
35. Penney JB, Jr, Vonsattel JP, MacDonald ME, et al. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 1997; 418: 689-692.
36. Belsely DA. Conditioning diagnostics collinearity and weak data in regression. New York: Wiley; 1991.
37. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research. Principles and quantitative methods. New York: Van Nostrand Reinhold; 1982.
38. Kleinbaum DG, Kupper LL, Muller KE. Applied regression analysis and other multivariable methods, Second ed. Boston: PWS-Kent; 1988.
39. Paulsen JS, Hayden M, Scout JC, et al. Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol 2006; 63: 883-890.
40. Tabrizi SJ, Langbehn DR, Leavitt BR, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009; 8: 791-801.